Guardant Health director sells 6,674 shares

Guardant Health director Steve E. Krognes disclosed open-market sales totaling 6,674 GH shares on September 16, 2026 at weighted average prices in the high-$170 range.

Rhea-AI Filing Summary

Guardant Health, Inc. (GH) director Steve E. Krognes reported selling a total of 6,674 shares of common stock on September 16, 2026 in four open-market or private transactions. Each sale was reported at a weighted average price with price ranges from $173.98 to $177.945 per share, and no Rule 10b5-1 trading plan is indicated.

Insider Trade Summary

Net Seller: 6,674 shares

Net Sell 4 txns

Insider Krognes Steve E.

Role Director

Sold 6,674 shs ($1.17M)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	1,103	$174.4623	$192K
Sale	Common Stock F2	3,300	$175.4206	$579K
Sale	Common Stock F3	1,300	$176.3354	$229K
Sale	Common Stock F4	971	$177.4766	$172K

Holdings After Transaction: Common Stock — 7,906 shares (Direct)

Footnotes (4)

1. F1. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $173.98 to $174.975. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
2. F2. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $175.02 to $176.01. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
3. F3. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $176.055 to $176.88. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
4. F4. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $177.08 to $177.945. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Key Figures

Total shares sold: 6,674 shares First tranche: 1,103 shares at $174.4623 Second tranche: 3,300 shares at $175.4206 +2 more

5 metrics

Total shares sold 6,674 shares Aggregate GH common shares sold by Steve E. Krognes on September 16, 2026

First tranche 1,103 shares at $174.4623 Weighted average price; individual trades ranged from $173.98 to $174.975

Second tranche 3,300 shares at $175.4206 Weighted average price; individual trades ranged from $175.02 to $176.01

Third tranche 1,300 shares at $176.3354 Weighted average price; individual trades ranged from $176.055 to $176.88

Fourth tranche 971 shares at $177.4766 Weighted average price; individual trades ranged from $177.08 to $177.945

Key Terms

weighted average sales price per share, open market or private transaction, multiple transactions

3 terms

weighted average sales price per share financial

"Represents the weighted average sales price per share."

open market or private transaction financial

"Sale in open market or private transaction"

multiple transactions financial

"These shares were sold in multiple transactions at prices ranging"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Guardant Health (GH) report for Steve E. Krognes?

Steve E. Krognes, a director of Guardant Health (GH), reported selling a total of 6,674 shares of GH common stock on September 16, 2026 in four separate open-market or private transactions.

How many Guardant Health (GH) shares did Steve E. Krognes sell in each transaction?

On September 16, 2026, Steve E. Krognes sold 1,103, 3,300, 1,300 and 971 GH common shares, respectively, across four reported transactions, for a total of 6,674 shares sold.

At what prices were Steve E. Krognes’ GH shares sold?

The sales used weighted average prices of $174.4623, $175.4206, $176.3354 and $177.4766 per share, with underlying trade price ranges from $173.98–$177.945 across the four transactions.

Were Steve E. Krognes’ Guardant Health (GH) stock sales under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is unchecked, and the footnotes describe only weighted average sales prices and price ranges, so no Rule 10b5-1 trading plan is reported for these transactions.

What type of transactions did Steve E. Krognes execute in Guardant Health (GH) stock?

All four reported trades are coded as “S”, described as sales in open market or private transactions of GH common stock on September 16, 2026, held as direct ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/17/2026 - 05:11 PM Accepted by SEC EDGAR 09/17/2026 - 05:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Krognes Steve E.

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/16/2026		S		1,103	D	$174.4623(1)	13,477	D
Common Stock	09/16/2026		S		3,300	D	$175.4206(2)	10,177	D
Common Stock	09/16/2026		S		1,300	D	$176.3354(3)	8,877	D
Common Stock	09/16/2026		S		971	D	$177.4766(4)	7,906	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $173.98 to $174.975. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

2. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $175.02 to $176.01. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

3. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $176.055 to $176.88. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

4. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $177.08 to $177.945. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

	/s/ John Saia, as attorney-in-fact for Steve Krognes	09/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)